l,4:3,6-Dianhydrohexitol Nitrate Derivatives. II.1) Synthesis and Antianginal Activity of Aryl- or Arylcarbonylpiperazine Derivatives2)

Abstract

A series of 5-(4-aryl- or 4-arylcarbonylpiperazin-l-yl)-5-deoxy-l,4:3,6-dianhydro-L-iditol 2-nitrates was prepared in order to obtain orally active, nitrate-type vasodilators with reduced side effects. Our drug design was based on a small reduction in the lipophilicity compared to that of 5-deoxy-5-[4-(3-phenylthiopropyl)piperazin-l-yl]-l,4:3,6-dianhydro-L-iditol 2-nitrate (1, KF14124). Compounds 4 h (aryl = benzimidazol-2-yl), 4i (arylcarbonyl = nicotinoyl), and 4w (arylcarbonyl = 3-furoyl) showed potent anti-ischemic activity in a lysine-vasopressin-induced angina pectoris model (rats), and their structure-activity relationships are discussed. Compound 4i exhibited potent vasodilation of the coronary artery in anesthetized dogs and also exhibited potent preload reducion in a heart failure model (dogs) as compared with isosorbide dinitrate (2), nicorandil (3), and KF14124 (1). Furthermore, 4i showed much weaker acute lethal toxicity and less central nervous system depression than 1 in mice. Thus, 4i (KW-3196) is under development as a vasodilator and a drug for treating angina pectoris. © 1993, The Pharmaceutical Society of Japan. All rights reserved.